LAMA/LABA Combo Duaklir Moves Closer To US Filing
AstraZeneca has released positive top-line data from a new Phase III study of the LAMA/LABA combination, Duaklir, in COPD that could lead to a US NDA filing in 2018, and the start of US marketing by partner Circassia.
You may also be interested in...
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.